National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Dictionary of Cancer Terms
In English   En español
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
In English   En español

gemtuzumab ozogamicin (gem-TOO-zeh-mab oh-zoh-GAM-ih-sin)

 A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Gemtuzumab ozogamicin is a type of antibody-drug conjugate. Also called gemtuzumab and Mylotarg.



Previous Definitions:GEM 231, GEM640, gemcitabine, gemcitabine hydrochloride, gemtuzumab
Next Definitions:Gemzar, Genasense, gene, gene deletion, gene expression

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov